
Opinion|Videos|July 23, 2025
Epidemiology Associated With Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Ungar: What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice?
- Is there a population in which AA occurs more frequently based on your clinical experience?
- Is there a population in which AA occurs more frequently based on your clinical experience?
Advertisement
Related to this article

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5


